Bio-Path Holdings, Inc. (OTCQB: BPTH), a clinical-stage biotechnology company, is making notable progress with its RNA interference (RNAi) therapeutics, leveraging its proprietary DNAbilize® platform. This technology enhances the delivery of antisense oligonucleotides, improving drug stability and cellular uptake while reducing toxicity. The company's lead candidate, prexigebersen (BP1001), is currently in Phase 2 trials for acute myeloid leukemia (AML), with a modified version, BP1001-A, showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes.
Another candidate, BP1002, targeting the Bcl-2 protein, is under evaluation for blood cancers and solid tumors, with a Phase 1 trial for refractory/relapsed AML progressing to its fourth dose cohort. Additionally, BP1003, a STAT3 inhibitor aimed at pancreatic cancer, is in pre-clinical development, demonstrating success in penetrating pancreatic tumors in previous studies.
Bio-Path's DNAbilize® technology represents a breakthrough in antisense and liposome delivery, offering a novel approach to treating a wide range of indications, including cancer. The company's strong intellectual property position and strategic relationships with leading cancer centers underscore its potential to revolutionize RNAi therapeutics. Despite a reported cash on hand of $122,000 as of March 31, 2025, and the need for additional funding, Bio-Path's pipeline of drug candidates and nearing Phase 2 milestones suggest significant undervaluation compared to peers.
The advancements in Bio-Path's clinical trials and technology platform highlight the importance of RNAi therapeutics in addressing unmet medical needs in oncology and metabolic diseases. The potential approval of its lead drug candidates could have a profound impact on patients worldwide, offering new hope for those with limited treatment options.
